Cargando…
Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies
In December 2020, an interim recommendation for the use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years was made under Food and Drug Administration’s Emergency Use Authorization. In preparation for Biologics License Application approval, we conducted a systematic review and meta-analys...
Autores principales: | Wallace, Megan, Collins, Jennifer P., Moline, Heidi, Plumb, Ian D., Godfrey, Monica, Morgan, Rebecca L., Campos-Outcalt, Doug, Oliver, Sara E., Dooling, Kathleen, Gargano, Julia W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9725157/ https://www.ncbi.nlm.nih.gov/pubmed/36473010 http://dx.doi.org/10.1371/journal.pone.0278624 |
Ejemplares similares
-
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
por: Dooling, Kathleen, et al.
Publicado: (2021) -
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
por: Oliver, Sara E., et al.
Publicado: (2020) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022)